Characterization of vertigo and hearing loss in patients with Fabry disease

[1]  C. Wanner,et al.  Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry disease , 2017, PloS one.

[2]  R. Reisin,et al.  Neuro-Otological and Peripheral Nerve Involvement in Fabry Disease , 2017, Audiology research.

[3]  C. Wanner,et al.  Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y , 2016, BMJ Open.

[4]  P. Hawkins,et al.  DPD Scintigraphy for diagnosis of amyloidosis in 1191 patients– a single centre experience , 2015, Orphanet Journal of Rare Diseases.

[5]  M. Rudnicki,et al.  Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document , 2015, Orphanet Journal of Rare Diseases.

[6]  A. Mehta,et al.  The N215S mutation results in a distinct subtype of Fabry disease , 2015 .

[7]  J. England,et al.  Fabry's disease , 2014, Journal of the Neurological Sciences.

[8]  M. Beer,et al.  Gene Mutations Versus Clinically Relevant Phenotypes: Lyso-Gb3 Defines Fabry Disease , 2014, Circulation. Cardiovascular genetics.

[9]  J. Colebatch,et al.  Vestibular evoked myogenic potentials: Past, present and future , 2010, Clinical Neurophysiology.

[10]  G. Paludetti,et al.  Inner ear involvement in Anderson-Fabry disease: long-term follow-up during enzyme replacement therapy. , 2010, Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale.

[11]  U. Ramaswami,et al.  Ear symptoms in children with Fabry disease: data from the Fabry Outcome Survey , 2009, Journal of Inherited Metabolic Disease.

[12]  Y. Chien,et al.  Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later‐onset GLA mutation c.936+919G>A (IVS4+919G>A) , 2009, Human mutation.

[13]  Shing‐Jong Lin,et al.  High Incidence of the Cardiac Variant of Fabry Disease Revealed by Newborn Screening in the Taiwan Chinese Population , 2009, Circulation. Cardiovascular genetics.

[14]  E. Mayatepek,et al.  Fabry disease-often seen, rarely diagnosed. , 2009, Deutsches Arzteblatt international.

[15]  D. Zee,et al.  How Often is Dizziness from Primary Cardiovascular Disease True Vertigo? A Systematic Review , 2008, Journal of General Internal Medicine.

[16]  G. M. Halmagyi,et al.  Ocular vestibular evoked myogenic potentials to bone conducted vibration of the midline forehead at Fz in healthy subjects , 2008, Clinical Neurophysiology.

[17]  J. E. Wraith,et al.  Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. , 2008, The Journal of pediatrics.

[18]  S. Iwasaki,et al.  Vestibular-evoked extraocular potentials by air-conducted sound: Another clinical test for vestibular function , 2007, Clinical Neurophysiology.

[19]  D. Straumann,et al.  Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy , 2007, Journal of Neurology.

[20]  P. Elliott,et al.  Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa , 2007, Heart.

[21]  J. Charrow,et al.  Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. , 2007, Journal of the American Society of Nephrology : JASN.

[22]  A. Keilmann,et al.  Hörstörungen bei Morbus Fabry , 2007, HNO.

[23]  J M Dambrosia,et al.  Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease. , 2006, Brain : a journal of neurology.

[24]  R. Desnick,et al.  High incidence of later-onset fabry disease revealed by newborn screening. , 2006, American journal of human genetics.

[25]  C. Ozdoba,et al.  Fabry's Disease: Otoneurologic Findings in Twelve Members of One Family , 2006, The Annals of otology, rhinology, and laryngology.

[26]  R. Schiffmann,et al.  Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  A. Mehta,et al.  Clinical manifestations of Fabry disease in children: Data from the Fabry Outcome Survey , 2006, Acta paediatrica.

[28]  H. Neuhauser,et al.  Epidemiology of vestibular vertigo , 2005, Neurology.

[29]  D. Basta,et al.  Normative data for P1/N1-latencies of vestibular evoked myogenic potentials induced by air- or bone-conducted tone bursts , 2005, Clinical Neurophysiology.

[30]  A. Mehta,et al.  Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey , 2004, European journal of clinical investigation.

[31]  G. Conti,et al.  Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females , 2003, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[32]  K. Macdermot,et al.  Hearing improvement in patients with Fabry disease treated with agalsidase alfa , 2003, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[33]  T. Proffitt,et al.  The effects of click and tone-burst stimulus parameters on the vestibular evoked myogenic potential (VEMP). , 2003, Journal of the American Academy of Audiology.

[34]  S. Packman,et al.  Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy , 2003, Annals of Internal Medicine.

[35]  P. Avan,et al.  Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients , 2002, BMC Medical Genetics.

[36]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[37]  John Hardy,et al.  The Siblings With Ischemic Stroke Study (SWISS) Protocol , 2002, BMC Medical Genetics.

[38]  K. Macdermot,et al.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males , 2001, Journal of medical genetics.

[39]  P. Fransson,et al.  Symmetry measures of vestibular evoked myogenic potentials using objective detection criteria , 2001, Scandinavian audiology.

[40]  P. Meikle,et al.  Prevalence of lysosomal storage disorders. , 1999, JAMA.

[41]  M. Dolgin,et al.  Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels , 1994 .

[42]  M. Paparella,et al.  Otologic Histopathology of Fabry's Disease , 1989, The Annals of otology, rhinology, and laryngology.

[43]  R. Schiffmann.  Fabry disease. , 2009, Pharmacology & therapeutics.

[44]  P. Luna,et al.  [Fabry disease]. , 2009, Anais brasileiros de dermatologia.

[45]  G. Wolf,et al.  Leptin and renal disease. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[46]  K Doqi,et al.  clinical practice guidelines for chronic kidney disease : evaluation, classification, and stratification , 2002 .

[47]  D. Germain.  A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant. , 2001, Contributions to nephrology.

[48]  A. Spoor,et al.  Presbycusis Values in Relation to Noise Induced Hearing Loss , 1967 .